Mesoblast Limited Sustainability Profile
Mesoblast Limited, an innovative leader in regenerative medicine, is headquartered in Australia and operates extensively across North America, Europe, and Asia. Founded in 2004, the company has made significant strides in developing advanced cell-based therapies, particularly in the fields of orthopaedics, cardiovascular diseases, and inflammatory conditions. Mesoblast's core products, including its proprietary allogeneic cell therapy platforms, are designed to address unmet medical needs with unique mechanisms of action that promote healing and tissue regeneration. The company has achieved notable milestones, including successful clinical trials and partnerships that enhance its market position in the biotechnology sector. With a commitment to transforming patient care, Mesoblast continues to be at the forefront of innovation in regenerative medicine.
DitchCarbon Score
How does Mesoblast Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mesoblast Limited's score of 16 is lower than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Mesoblast Limited's reported carbon emissions
Mesoblast Limited, headquartered in Australia, currently does not have available carbon emissions data for the most recent year. As a result, specific figures regarding their total emissions, including Scope 1, Scope 2, and Scope 3 emissions, are not provided. The company has not outlined any specific reduction targets or commitments related to climate action, nor have they made any pledges towards emissions reduction initiatives. This absence of data suggests that Mesoblast Limited may still be in the early stages of developing a comprehensive climate strategy or reporting framework. In the context of the industry, it is increasingly important for organisations to establish clear climate commitments and reduction targets to align with global sustainability goals. As such, Mesoblast Limited may benefit from adopting industry-standard practices in emissions reporting and climate action to enhance their environmental accountability.
How Carbon Intensive is Mesoblast Limited's Industry?
How Carbon Intensive is Mesoblast Limited's Location?
Mesoblast Limited's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Mesoblast Limited has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Orthofix
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.